Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients-Report of the Polish Myeloma Group

被引：5

作者：

Usnarska-Zubkiewicz, L. ^{[1
]}

Debski, J. ^{[1
]}

Butrym, A. ^{[1
,2
]}

Legiec, W. ^{[3
]}

Hus, M. ^{[3
]}

Dmoszynska, A. ^{[3
]}

Stella-Holowiecka, B. ^{[4
]}

Zaucha, J. M. ^{[5
]}

Januszczyk, J. ^{[5
]}

Rymko, M. ^{[6
]}

Torosian, T. ^{[7
]}

Charlinski, G. ^{[7
]}

Lech-Maranda, E. ^{[8
,9
]}

Malenda, A. ^{[8
]}

Jurczyszyn, A. ^{[10
]}

Urbariska-Rys, H. ^{[11
]}

Druzd-Sitek, A. ^{[12
,13
]}

Blonska, D. ^{[14
]}

Urbanowicz, A. ^{[15
]}

Holojda, J. ^{[16
]}

Pogrzeba, J. ^{[17
]}

Rzepecki, P. ^{[18
]}

Halka, J. ^{[18
]}

Subocz, E. ^{[18
]}

Becht, R. ^{[19
]}

Zdziarska, B. ^{[19
]}

Dytfeld, D. ^{[20
]}

Nowicki, A. ^{[20
]}

Bolkun, L. ^{[21
]}

Kloczko, J. ^{[21
]}

Knopinska-Posluszny, W. ^{[22
]}

Zubkiewicz-Kucharska, A. ^{[23
]}

Kuliczkowski, K. ^{[1
]}

机构：

[1] Wroclaw Med Univ, Dept Haematol Blood Neoplasms & Bone Manow Transp, Wroclaw, Poland

[2] Wroclaw Med Univ, Dept Physiol, Wroclaw, Poland

[3] Med Univ Lublin, Dept Haematol & Bone Manow Transplantat, Lublin, Poland

[4] Med Univ Silesia, Dept Haematol & Bone Manow Transplantat, Katowice, Poland

[5] Gdynia Oncol Ctr, Gdynia, Poland

[6] Dist Hosp Torun, Dept Haematol, Torun, Poland

[7] Med Univ Warsaw, Dept Haematol Oncol & Internal Med, Warsaw, Poland

[8] Inst Hematol & Blood Transfus, Dept Haematol, Warsaw, Poland

[9] Ctr Postgrad Med Educ, Warsaw, Poland

[10] Jagiellonian Univ, Coll Med, Dept Haematol, Krakow, Poland

[11] Med Univ Lodz, Dept Haematol, Lodz, Poland

[12] Maria Sklodowska Curie Mem Inst Oncol, Dept Lymphoproliferat Dis, Warsaw, Poland

[13] Ctr Oncol, Warsaw, Poland

[14] Dept Haematol & Neoplasmat Dis Haematopoiesis, Bydgoszcz, Poland

[15] Dist Hosp Suwalki, Dept Clin Oncol & Haematol, Suwalki, Poland

[16] Dist Specialist Hosp Legnica, Dept Haematol, Legnica, Poland

[17] Dist Hosp Opole, Dept Haematol & Haematooncol, Opole, Poland

[18] Minist Natl Def, Cent Clin Hosp, Mil Inst Med, Dept Internal Dis & Haematol, Warsaw, Poland

[19] Pomeranian Med Univ, Dept Haematol, Szczecin, Poland

[20] Poznan Univ Med Sci, Dept Haematol & Bone Manow Transplantat, Poznan, Poland

[21] Univ Clin Hosp Bialystok, Dept Haematol, Bialystok, Poland

[22] Warmia & Masuria Oncol Ctr, Minist Interior Hosp Olsztyn, Warmia, Poland

[23] Wroclaw Med Univ, Dept Endocrinol & Diabetol Children & Adolescents, Wroclaw, Poland

来源：

LEUKEMIA RESEARCH | 2016年 / 40卷

关键词：

Multiple myeloma; Lenalidomide; Efficacy; Safety; PLUS DEXAMETHASONE; FOLLOW-UP; THERAPY; THALIDOMIDE; THROMBOSIS; SURVIVAL;

D O I：

10.1016/j.leukres.2015.11.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of the multi-centre retrospective study was to evaluate the efficacy and safety of lenalidomide (LEN) therapy in patients with resistant or relapsed multiple myeloma (MM) as well as in patients with stable disease (LEN used due to neurological complications). The primary endpoint of this study was an overall response rate (ORR). The secondary endpoints were as follows: time to progression (TTP), overall survival (OS) and the safety of drug use. Data were collected in 19 centres of the Polish Multiple Myeloma Study Group. The study group consisted of 306 subjects: 153 females and 153 males. In 115 patients (38.8%, group A), a resistant myeloma was diagnosed; in 135 (44.1%, group B) a relapse, and in 56(18.3%, group C) a stable disease were stated. In 92.8% of patients, LEN + DEX combination was used; in remaining group, LEN monotherapy or a combination therapy LEN + bortezomib or LEN + bendamustine and other were used. In the entire study group, ORR was 75.5% (including 12.4% patients achieving complete remission [CR] or stringent CR [sCR]). Median time to progression (UP) was 20 months. Median overall survival (OS) was 33.3 months. The regression model for "treatment response" was on the borderline of statistical significance (p = 0.07), however the number of LEN treatment cycles >= 6 (R-2 = 17.2%), baseline LDH level (R-2 = 1.1%) and no ASCT use (R-2 = 1.7%) where the factors most affecting treatment response achievement. The regression model for dependant variable - "overall survival" - was statistically significant (p = 0.0000004). Factors with the most impact on OS were as follows: number of LEN cycles treatment >= 6 (R-2 = 16.7%), treatment response achievement (R-2 = 6.9%), beta-2-microglobulin (beta-2-M) level (R-2 = 4.8%), renal function (R-2 = 3.0%) and lack of 314 grade adverse events (R-2 = 1.4%). Summary: LEN is an effective and safe therapeutic option, even in intensively treated resistant and relapsed MM patients, as well as in patients with stable disease and previous treatment-induced neurological complications. In particular, the number of LEN treatment cycles >= 6 was the factor which affected treatment response achievement the most, together with an important impact on OS. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：90 / 99

页数：10

共 50 条

[1] EFFICACY AND SAFETY OF LENALIDOMIDE IN THE TREATMENT OF MULTIPLE MYELOMA WITH RENAL INSUFFICIENCY
Bernal, L.
Bonafonte, E.
Izquierdo, I.
Aules, A.
Malo, M.
Olave, M.
Azaceta, G.
Gutierrez, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 628 - 629
[2] Lenalidomide Treatment of Multiple Myeloma (MM) and Other Neoplasms
Martinez, Pablo del Pino
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 33 - 36
[3] EFFICACY AND SAFETY OF LENALIDOMIDE IN PATIENTS WITH MULTIPLE MYELOMA COMPLICATED BY EXTRAMEDULLARY PLASMACYTOMAS
Calvo, J. M.
Alegre, A.
Garcia-Sanchez, R.
Hernandez, M. T.
Giraldo, P.
Zudaire, M.
Gusmao, B.
Rodriguez, J. N.
Calle, C.
Ramirez, G.
Inigo, B.
Martinez, J.
Oriol, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 588 - 588
[4] Efficacy and safety of lenalidomide and dexamethasone in overtreated multiple myeloma patients.
Moscetti, Alessandro
Resci, Federica
Antolino, Giusy
Saltarelli, Francesca
Monarca, Bruno
Bianchi, Maria Paola
Naso, Virginia
De Benedittis, Daniela
La Verde, Giacinto
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[5] Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
Alegre, Adrian
Vicuna, Isabel
Aguado, Beatriz
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
[6] EFFICACY AND SAFETY OF THE TREATMENT WITH LENALIDOMIDE IN LONG TERM IN PATIENTS WITH MULTIPLE MYELOMA. EXPERIENCE OF A CENTRE
Saucedo Alejandro, Marin
Ana, Sanchez
Pablo, Rios
Joaquin, Brena
Cristina, Notario
Hector, Gonzalez
Ana, Cabello
Carmen, Marrero
Nuria, Hernanz
Ana, Oliva
Antonio, Leon
Mario, Rios
Alexander, Figueroa
Patricia, Hernandez
Yaxiraxi, Lorenzo
Maria Carmen, Mesa
HAEMATOLOGICA, 2016, 101 : 305 - 305
[7] HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT - A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP
Hus, I.
Manko, J.
Jawniak, D.
Jurczyszyn, A.
Usnarska-Zubkiewicz, L.
Sawicki, M.
Charlinski, G.
Razny, M.
Rodzaj, M.
Waszczuk-Gajda, A.
Drozd-Sokolowska, J.
Galazka, A.
Swiderska, A.
Poglodek, B.
Pluta, A.
Druzd-Sitek, A.
Grzasko, N.
Kopinska, A.
Pasternak, A.
Blonska, D.
Hus, M.
Dmoszynska, A.
HAEMATOLOGICA, 2017, 102 : 515 - 515
[8] A comparison of the efficacy and safety of ixazomib and lenalidomide combined with dexamethasone in the treatment of multiple myeloma
Zheng, Zhipan
Lin, Kai
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (05): : 5248 - 5255
[9] Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
M A Dimopoulos
A S Swern
J S Li
M Hussein
L Weiss
Y Nagarwala
R Baz
Blood Cancer Journal, 2014, 4 : e257 - e257
[10] Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
Dimopoulos, M. A.
Swern, A. S.
Li, J. S.
Hussein, M.
Weiss, L.
Nagarwala, Y.
Baz, R.
BLOOD CANCER JOURNAL, 2014, 4 : e257 - e257

← 1 2 3 4 5 →